Everand Logo

Welcome to Everand!

  • STAT

    Opinion: The Senate can change the course of the opioid crisis. Here are 50 ways it can do that

    Senators: to craft a bill that can really solve the opioid epidemic, ask people with addiction and their family members for advice, and then listen to them.
    by Devin Oller Sep 05, 2018 5 minutes
    Making it easier for doctors to prescribe and deliver methadone and other medications proven to reduce opioid-use-disorder is one way the Senate can ease the overdose epidemic.

    As overdose deaths from opioids and other drugs continue to rise — they are up almost 7 percent from the previous year — the U.S. Senate has a choice to make. It can change the course of this crisis or let the country continue to lag behind in addressing this public health emergency.

    One of the Senate’s many tasks this session is to craft a bill that addresses the opioid crisis using the scaffolding set by the SUPPORT for Patients and Communities Act (), which passed the House of Representatives in June. SUPPORT is an important starting point, but is limited in its scope and lacks essential provisions that would lower barriers for patients struggling with addiction to get help. SUPPORT may look good on the resume of a congressperson running for

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About FDA Dithering On Pharma Patents, WHO Pandemic Talks, And More
    When it comes to a crucial controversy over patents for drug-and-device combination products, the FDA has been MIA.
    STAT1 min read
    STAT+: Element Biosciences, An Illumina Rival, On Its Genomics Ambitions — And Why It Hasn’t Gone Public
    Element Biosciences' modest growth comes at a time when some other players are struggling in a sequencer market dominated by Illumina.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Boy Dying In Pfizer Trial; AstraZeneca Yanking Covid Shot, And More
    A young boy died in a clinical trial for an experimental Pfizer gene therapy for Duchenne muscular dystrophy, about a year after receiving the therapy.

    Related Books & Audiobooks